JP2024083460A5 - - Google Patents

Download PDF

Info

Publication number
JP2024083460A5
JP2024083460A5 JP2024060790A JP2024060790A JP2024083460A5 JP 2024083460 A5 JP2024083460 A5 JP 2024083460A5 JP 2024060790 A JP2024060790 A JP 2024060790A JP 2024060790 A JP2024060790 A JP 2024060790A JP 2024083460 A5 JP2024083460 A5 JP 2024083460A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
tablet
weight
microcrystalline cellulose
high grade
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024060790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024083460A (ja
Filing date
Publication date
Priority claimed from JP2021507989A external-priority patent/JP7469293B2/ja
Application filed filed Critical
Publication of JP2024083460A publication Critical patent/JP2024083460A/ja
Publication of JP2024083460A5 publication Critical patent/JP2024083460A5/ja
Pending legal-status Critical Current

Links

JP2024060790A 2018-08-17 2024-04-04 Ag10の製剤 Pending JP2024083460A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862765154P 2018-08-17 2018-08-17
US62/765,154 2018-08-17
JP2021507989A JP7469293B2 (ja) 2018-08-17 2019-08-16 Ag10の製剤
PCT/US2019/046789 WO2020037189A1 (en) 2018-08-17 2019-08-16 Formulations of ag10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021507989A Division JP7469293B2 (ja) 2018-08-17 2019-08-16 Ag10の製剤

Publications (2)

Publication Number Publication Date
JP2024083460A JP2024083460A (ja) 2024-06-21
JP2024083460A5 true JP2024083460A5 (enExample) 2024-11-28

Family

ID=69524257

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021507989A Active JP7469293B2 (ja) 2018-08-17 2019-08-16 Ag10の製剤
JP2024060790A Pending JP2024083460A (ja) 2018-08-17 2024-04-04 Ag10の製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021507989A Active JP7469293B2 (ja) 2018-08-17 2019-08-16 Ag10の製剤

Country Status (23)

Country Link
US (2) US11260047B2 (enExample)
EP (2) EP3836920B1 (enExample)
JP (2) JP7469293B2 (enExample)
KR (1) KR20210046708A (enExample)
CN (1) CN112804998A (enExample)
AU (2) AU2019321583C1 (enExample)
BR (1) BR112020026493A2 (enExample)
CA (1) CA3104695A1 (enExample)
CL (1) CL2021000289A1 (enExample)
DK (1) DK3836920T3 (enExample)
EA (1) EA202190561A1 (enExample)
FI (1) FI3836920T3 (enExample)
HR (1) HRP20251603T1 (enExample)
IL (1) IL280906B1 (enExample)
LT (1) LT3836920T (enExample)
MA (1) MA53238A (enExample)
MX (1) MX2021001761A (enExample)
PT (1) PT3836920T (enExample)
SG (1) SG11202101393PA (enExample)
SM (1) SMT202500463T1 (enExample)
TW (1) TWI834708B (enExample)
UA (1) UA128256C2 (enExample)
WO (1) WO2020037189A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021015220A (es) 2017-02-17 2022-12-01 Eidos Therapeutics Inc Procesos para preparar ácido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo.
CA3094711A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
WO2020037189A1 (en) 2018-08-17 2020-02-20 Eidos Therapeutics, Inc. Formulations of ag10
WO2023052652A1 (en) 2021-10-01 2023-04-06 Sandoz Ag Crystalline form of acoramidis hydrochloride
WO2025235883A1 (en) 2024-05-10 2025-11-13 Eidos Therapeutics, Inc. Acoramidis for use in the treatment of renal dysfunction

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4255329A (en) 1973-10-02 1981-03-10 Syva Company Double receptor fluorescent immunoassay
US4117149A (en) 1975-09-12 1978-09-26 Pfizer Inc. 4-oxo-4h-benzopyrans as animal growth promotants
US4261928A (en) 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4171365A (en) 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
US4234725A (en) 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4232161A (en) 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4668640A (en) 1981-12-11 1987-05-26 Abbott Laboratories Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB2120242A (en) 1982-04-30 1983-11-30 Erba Farmitalia Ergoline derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4764521A (en) 1983-07-18 1988-08-16 Eli Lilly And Company Leukotriene antagonists and a method of use there as
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5315015A (en) 1992-11-10 1994-05-24 Hoffmann-La Roche Inc. Compounds having improved fluorescence in fluorescence polarization immunoassays and immunoassays utilizing same
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
WO1994022857A1 (fr) 1993-04-07 1994-10-13 Taiho Pharmaceutical Co., Ltd. Derive de thiazolidine et composition pharmaceutique contenant ce derive
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
NZ334914A (en) 1996-10-01 2000-09-29 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
KR100719273B1 (ko) 1997-10-28 2007-05-18 반도 카가쿠 가부시키가이샤 피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2003043998A1 (en) 2001-11-15 2003-05-30 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
AU2003249678B2 (en) 2002-05-31 2009-03-19 Protamed, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease
WO2004096808A1 (en) 2003-04-28 2004-11-11 De Novo Pharmaceuticals Limited Triazine compounds and their use
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006088694A1 (en) 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
WO2007012022A2 (en) 2005-07-18 2007-01-25 Horizon Therapeutics, Inc. Unit dose form with ibuprofen-famotidine admixture
EP2102165A2 (en) 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
EA200900821A1 (ru) 2006-12-22 2010-02-26 Новартис Аг Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
DK2155717T3 (da) 2007-05-11 2012-11-19 Lilly Co Eli 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl-pyraziner og -pyridiner og 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl-pyridiner som 5-ht7-receptorantagonister
KR20100017372A (ko) 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2(mglu2 수용체)의 포지티브 조절자로서의 헤테로사이클릭 화합물
EA019084B1 (ru) 2007-06-06 2014-01-30 Торрент Фармасьютикалс Лтд. Новые тиреоидные соединения для лечения заболеваний, связанных с нарушением обмена веществ
MX2009013213A (es) 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
PT2260020E (pt) 2008-03-26 2014-10-28 Novartis Ag Inibidores das desacetilases b baseados no hidroxamato
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
MX344354B (es) 2008-10-20 2016-12-14 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion de transtiretina.
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
CN104945382B (zh) 2009-10-14 2020-02-07 默沙东公司 提高p53活性的取代的哌啶和其用途
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
EP2651957B1 (en) 2010-12-16 2015-02-18 Allergan, Inc. Phosphorous derivatives as chemokine receptor modulators
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
WO2016025129A1 (en) 2014-08-14 2016-02-18 Alhamadsheh Mamoun M Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
ES2945345T3 (es) 2015-06-30 2023-06-30 Gilead Sciences Inc Formulaciones farmacéuticas
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
TW202332423A (zh) * 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
MX2021015220A (es) 2017-02-17 2022-12-01 Eidos Therapeutics Inc Procesos para preparar ácido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo.
CA3094711A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
WO2020037189A1 (en) 2018-08-17 2020-02-20 Eidos Therapeutics, Inc. Formulations of ag10

Similar Documents

Publication Publication Date Title
JP2024083460A5 (enExample)
NO320844B1 (no) Celecoxibpreparat, fremgangsmate for fremstilling av dette og av farmasoytisk preparat som omfatter det og anvendelse av celeboxibpreparatet for fremstilling av preparat og medikament.
CN103974695A (zh) 苦味被遮蔽的枸橼酸西地那非口服薄膜制剂
CN105073099B (zh) 有机化合物的制剂
WO2001043747A1 (fr) Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
US8097267B2 (en) Moisture resistant container systems for rapidly bioavailable dosage forms
TWI658841B (zh) 包含苯并咪唑衍生物的新穎調配物
JP7537032B2 (ja) ラサギリン又はその医薬用塩の舌下フィルム剤及びその製造方法、使用
JP2024522817A (ja) フェニルピロールアミノグアニジン塩及び製剤
TW202021583A (zh) Ag10之調配物
JP6335269B2 (ja) 医薬ソフトゼラチンカプセル剤形
JP6335270B2 (ja) 変性グアーガムを用いる医薬ソフトゼラチンカプセル剤形
JP4185974B2 (ja) カリウム、ナトリウムおよびトリスオキサプロジン塩医薬組成物
JP2018118966A5 (enExample)
JP6758488B2 (ja) カンデサルタンおよびアムロジピンを含む単一層からなる複合製剤
JP2023548348A (ja) 固体製剤
EP1259261A1 (en) Pharmaceutical compositions comprising terbinafine
WO2013119607A2 (en) Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
JP7355846B2 (ja) 固形製剤
JP2017530137A (ja) アムロジピン及びロサルタンを含む固形医薬組成物
US20060188565A1 (en) Rapidly bioavailable tablet and capsule formulations of diclofenac
JP2019504866A (ja) 新規組成物
JPWO2020252014A5 (enExample)
TR2023006082T2 (tr) Asemetazi̇ni̇n stabi̇l sürekli̇ salimli kompozi̇syonlari
JPWO2019074826A5 (enExample)